Drug Profile
Research programme: CD40 agonists - Apogenix
Alternative Names: APG 1233; APG 1274; HERA-CD40L; scCD40L-RBD-FcLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Apogenix
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD40 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Solid-tumours in Germany
- 10 Apr 2021 Pharmacodynamics data from a preclinical trial in cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 22 Jun 2020 Preclinical development is ongoing in Germany